Clinical trial
Investigating the Role of a4b7 Integrin as a Therapeutic Target in Eosinophilic Esophagitis
NCT02546219 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Investigating the Role of a4b7 Integrin as a Therapeutic Target in Eosinophilic Esophagitis
- Lead sponsor
- Massachusetts General Hospital
- Phase
- Observational
- Overall status
- Completed
- Start date
- March 31, 2016
- Completion date
- December 31, 2018
- Enrollment
- 16 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.